This HTML5 document contains 38 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n12http://linked.opendata.cz/resource/drugbank/drug/DB05347/identifier/pubchem-compound/
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n11http://linked.opendata.cz/resource/drugbank/drug/DB05347/identifier/drugbank/
n4http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n9http://linked.opendata.cz/resource/drugbank/drug/DB05347/identifier/chemspider/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n6http://linked.opendata.cz/ontology/drugbank/
owlhttp://www.w3.org/2002/07/owl#
n10http://linked.opendata.cz/resource/drugbank/drug/DB05347/identifier/wikipedia/
n7http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#

Statements

Subject Item
n2:DB05347
rdf:type
n6:Drug
n6:description
Acyclovir which has chemical name as acycloguanosine, is a guanine analogue antiviral drug, marketed under trade names such as Zovirax and Zovir (GSK). One of the most commonly-used antiviral drugs, it is primarily used for the treatment of herpes simplex virus infections, as well as in the treatment of herpes zoster (shingles).
n6:generalReferences
# Morrel EM, Spruance SL, Goldberg DI: Topical iontophoretic administration of acyclovir for the episodic treatment of herpes labialis: a randomized, double-blind, placebo-controlled, clinic-initiated trial. Clin Infect Dis. 2006 Aug 15;43(4):460-7. Epub 2006 Jul 3. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16838235 # Henley-Cohn J, Hausfeld JN: Iontophoretic treatment of oral herpes. Laryngoscope. 1984 Jan;94(1):118-21. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/6690869
n6:group
investigational
n6:indication
Investigated for use/treatment in herpes labialis infections (cold sores) and herpes simplex infections.
owl:sameAs
n4:DB05347
dcterms:title
iontophoretic acyclovir
adms:identifier
n9:1945 n10:Aciclovir n11:DB05347 n12:2022
n6:mechanismOfAction
The nominal efficacy of the topical formulation, acyclovir for the treatment of herpes labialis is due to inadequate penetration of the drug into the target site of infection, basal epidermis. To resolve this problem, a low-voltage, wireless, hand-held, computer-controlled, iontophoretic applicator has been developed to enhance the skin penetration of topical acyclovir. Aciclovir can be considered a prodrug: it is administered in an inactive (or less active form) and is metabolised into a more active species after administration. Acylovir differs from previous nucleoside analogues in that it contains only a partial nucleoside structure: the sugar ring is replaced by an open-chain structure. It is selectively converted into acyclo-guanosine monophosphate (acyclo-GMP) by viral thymidine kinase, which is far more effective (3000 times) in phosphorylation than cellular thymidine kinase. Subsequently, the monophosphate form is further phosphorylated into the active triphosphate form, acyclo-guanosine triphosphate (acyclo-GTP), by cellular kinases. Acyclo-GTP is a very potent inhibitor of viral DNA polymerase; it has approximately 100 times greater affinity for viral than cellular polymerase. As a substrate, acyclo-GMP is incorporated into viral DNA, resulting in chain termination. It has also been shown that viral enzymes cannot remove acyclo-GMP from the chain, which results in inhibition of further activity of DNA polymerase. Acyclo-GTP is fairly rapidly metabolised within the cell, possibly by cellular phosphatases.
n6:IUPAC-Name
n7:271B418F-363D-11E5-9242-09173F13E4C5
n6:InChI
n7:271B4195-363D-11E5-9242-09173F13E4C5
n6:Molecular-Formula
n7:271B4194-363D-11E5-9242-09173F13E4C5
n6:Molecular-Weight
n7:271B4191-363D-11E5-9242-09173F13E4C5
n6:Monoisotopic-Weight
n7:271B4192-363D-11E5-9242-09173F13E4C5
n6:SMILES
n7:271B4193-363D-11E5-9242-09173F13E4C5
n6:Water-Solubility
n7:271B418D-363D-11E5-9242-09173F13E4C5
n6:logP
n7:271B418E-363D-11E5-9242-09173F13E4C5 n7:271B418B-363D-11E5-9242-09173F13E4C5
n6:logS
n7:271B418C-363D-11E5-9242-09173F13E4C5
n6:H-Bond-Acceptor-Count
n7:271B419B-363D-11E5-9242-09173F13E4C5
n6:H-Bond-Donor-Count
n7:271B419C-363D-11E5-9242-09173F13E4C5
n6:InChIKey
n7:271B4196-363D-11E5-9242-09173F13E4C5
n6:Polar-Surface-Area--PSA-
n7:271B4197-363D-11E5-9242-09173F13E4C5
n6:Polarizability
n7:271B4199-363D-11E5-9242-09173F13E4C5
n6:Refractivity
n7:271B4198-363D-11E5-9242-09173F13E4C5
n6:Rotatable-Bond-Count
n7:271B419A-363D-11E5-9242-09173F13E4C5
n6:Bioavailability
n7:271B41A1-363D-11E5-9242-09173F13E4C5
n6:Ghose-Filter
n7:271B41A3-363D-11E5-9242-09173F13E4C5
n6:MDDR-Like-Rule
n7:271B41A4-363D-11E5-9242-09173F13E4C5
n6:Number-of-Rings
n7:271B41A0-363D-11E5-9242-09173F13E4C5
n6:Physiological-Charge
n7:271B419F-363D-11E5-9242-09173F13E4C5
n6:Rule-of-Five
n7:271B41A2-363D-11E5-9242-09173F13E4C5
n6:Traditional-IUPAC-Name
n7:271B4190-363D-11E5-9242-09173F13E4C5
n6:pKa--strongest-acidic-
n7:271B419D-363D-11E5-9242-09173F13E4C5
n6:pKa--strongest-basic-
n7:271B419E-363D-11E5-9242-09173F13E4C5